|
1
|
Wu M, Vadlakonda S, El-Kattan Y, Ghosh A, Lin TH, Chambers-Wilson R, Cheng X, Bantia S, Kellogg-Yelder D, Chand P, Babu YS, Kotian PL. Synthesis and biological evaluation of Ribo 7-N/O/S pyrimidine 9-deaza C-nucleoside analogs as new antiviral agents for inhibiting HCV RNA-dependent RNA polymerases. Eur J Med Chem 2024; 264:115991. [PMID: 38118393 DOI: 10.1016/j.ejmech.2023.115991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 11/20/2023] [Accepted: 11/21/2023] [Indexed: 12/22/2023]
Abstract
Hepatitis C infection is caused by the bloodborne pathogen hepatitis C virus (HCV) and can lead to serious liver diseases and, ultimately, death if the treatment is ineffective. This work reports the synthesis and preclinical evaluation of 7 novel 9-O/N/S pyrimidine nucleosides, including compound 12, the triphosphate of known compound 7b. The nucleosides are 9-deaza modifications of adenosine and guanosine with β-2'-C-methyl substituent on the ribose. Within this series of compounds, a 9-deaza furopyrimidine analog of adenosine, compound 7b, showed high anti-HCV activity in vitro, good stability, low toxicity, and low genotoxicity when administrated in low doses, and an adequate pharmacokinetics profile. An improved synthesis of compound 7b compared to a previous study is also reported. Compound 12 was synthesized as a control to verify phosphorylation of 7b occurred in vivo.
Collapse
Affiliation(s)
- Minwan Wu
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA
| | - Satish Vadlakonda
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA
| | - Yahya El-Kattan
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA
| | - Ajit Ghosh
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA.
| | - Tsu-Hsing Lin
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA
| | - Ramanda Chambers-Wilson
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA
| | - Xiaogang Cheng
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA
| | - Shanta Bantia
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA.
| | - Debra Kellogg-Yelder
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA
| | - Pooran Chand
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA.
| | - Y S Babu
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA
| | - Pravin L Kotian
- BioCryst Pharmaceuticals Inc., Discovery Center of Excellence, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, Alabama 35244, USA.
| |
Collapse
|